Clinical trials: Oral Anticoagulant
Atrial Fibrillation
PRescriptiOn PattERns Of Oral Anticoagulants
Atrial fibrillation is the major cause of acute ischemic stroke. The risk of stroke was shown to decline by oral anticoagulant therapy.
- Trial name
- PROPER (NCT02366338)
- Volunteers
- 148 people
- Sponsor
- Muğla Sıtkı Koçman University
Acute Ischemic Stroke
Intravenous Thrombolysis and NOAC
New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT06749834
- Testing
- Intravenous thrombolysis
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Non-valvular Atrial Fibrillation
Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation
This is a prospective, single-center, randomized, exploratory clinical observation to explore the overall benefit of short-term dual antiplatelet or novel oral anticoagulant regimens after left atrial appendage (LAA) occlusion by…
- Trial name
- NCT05761704
- Testing
- Dual antiplatelet, Novel oral anticoagulant
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Femur Fracture
Assessment of a Procedure for Managing Oral Anticoagulants (NACO) in the Management of Fractures
The purpose of this study is to demonstrate that by allowing patients with an anticoagulant level less than 100 ng/ml to have their fracture managed surgically, will reduce the delay in surgery and therefore the complications…
- Trial name
- STOP-NACO (NCT06220422)
- Testing
- Standard Department procedure for managing direct-acting oral anticoagulants, New Department procedure for managing direct-acting oral anticoagulants
- Where
- France
- Volunteers
- 127 people
- Sponsor
- Hôpital NOVO
Deep Venous Thrombosis, Pulmonary Embolism
Drug Interaction Between Paracetamol and Warfarin
The objective of this study is to investigate whether paracetamol, given at therapeutic doses (2g/day and 3 g/day), may potentiate the anticoagulant effect of warfarin.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Stroke
- Trial name
- INPAWA2 (NCT01104337)
- Testing
- paracetamol
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hopital Lariboisière
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Thromboembolism, Hemodialysis
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
The purpose of this study is to better understand if either dalteparin or tinzaparin is a better drug to use in dialysis patients on blood thinners who are at high risk of developing blood clots and need surgery.
- Trial name
- NCT00260988
- Testing
- Fragmin (dalteparin), Innohep (tinzaparin)
- Where
- 2 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Ottawa Hospital Research Institute
Adherence, Medication, Statin Adverse Reaction
Medicines Gaps Study
The adherence project aims to understand adherence rates and barriers to Direct oral anticoagulants (DOACs) and statins and improve awareness of healthcare professionals on adherence across Leeds.
- Conditions
- Adherence, Medication, Statin Adverse Reaction, Anticoagulant Adverse Reaction
- Trial name
- MeGa (NCT05332158)
- Testing
- Questionnaires to report barriers to medication adherence
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Direct Oral Anticoagulants (DOACs)
LED Application Following Dental Extraction in Patients Taking Direct Oral Anticoagulants.
The DENT-DOAC trial is a single-blinded RCT investigating the effectiveness of LED application following dental extractions in patients taking direct oral anticoagulants (DOACs) .
- Trial name
- DENT-DOAC (NCT06971081)
- Testing
- LED light
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Ischemic Stroke, TIA
Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral…
- Trial name
- TRACE (NCT01923818)
- Testing
- rivaroxaban, Aspirin
- Where
- China
- Volunteers
- 3,700 people
- Sponsor
- Xijing Hospital
Therapeutic Drug Monitoring
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.
Non-vitamin K antagonist oral anticoagulant (NOAC) is the first line therapy to prevent thromboembolism in atrial fibrillation (AF) patients.
- Trial name
- NCT05283174
- Testing
- Blood sampling to test drug level
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Prothrombin Complex Factor Deficiency
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
The purpose of the study is to assess the efficacy and safety of Prothromplex Total as a treatment for the immediate reversal of oral anticoagulant therapy with vitamin K antagonists in patients with acquired deficiency of…
- Trial name
- NCT01159210
- Testing
- Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)
- Where
- 6 sites in Austria, Hungary
- Volunteers
- 61 people
- Sponsor
- Baxalta now part of Shire
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thrombus of Left Ventricle
Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era
The investigators' primary objective is to assess whether a difference in the occurrence of bleeding events exist between patients with LVT treated with DOACs as compared to those treated with VKAs.
- Trial name
- LV-Thrombus (NCT05028777)
- Where
- Switzerland
- Volunteers
- 98 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Antiphospholipid Syndrome (APS), Cohort Study
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier…
- Conditions
- Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events
- Trial name
- DOWAPS (NCT06884384)
- Testing
- Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml), Completion of a questionnaire on compliance with anticoagulant treatment, Completion of a questionnaire on satisfaction with treatment anticoagulant
- Where
- 13 sites in France
- Volunteers
- 310 people
- Sponsor
- Central Hospital, Nancy, France
Cirrhosis, Esophageal and Gastric Varices
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing…
- Conditions
- Cirrhosis, Esophageal and Gastric Varices, Ascites, Hepatic Encephalopathy
- Trial name
- APIXABAN-PK (NCT07521332)
- Testing
- Apixaban, Carvedilol
- Where
- Pakistan
- Volunteers
- 220 people
- Sponsor
- Asian Institute Of Medical Sciences
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Bleeding
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding.
- Trial name
- NCT06575517
- Sponsor
- AstraZeneca
Stroke
Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.
AiCure uses artificial intelligence and visual recognition technology to confirm medication ingestion. The software is available as an app and downloaded onto a smart phone.
- Trial name
- NCT02599259
- Testing
- Monitored (M+)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AiCure